Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Tebentafusp-tebn in Combination With Liver-Directed Therapies for the Treatment of Metastatic Uveal Melanoma

NCT06626516 is registered in ClinicalTrials.gov with Thomas Jefferson University as lead sponsor.

NCT NCT06626516
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06626516 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Tebentafusp-tebn in Combination With Liver-Directed Therapies for the Treatment of Metastatic Uveal Melanoma
Lead sponsor
Thomas Jefferson University
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 15, 2025
Completion date
August 31, 2032
Enrollment
109 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic uveal melanoma